Ebglyss (lebrikizumab) Letter of Medical Necessity
Ebglyss (lebrikizumab) is an IL-13–specific monoclonal antibody FDA-approved in September 2023 for moderate-to-severe atopic dermatitis. It joins dupilumab and tralokinumab in the biologic AD class. PA typically requires prior dupilumab trial (step therapy) on most plans. Once approved, its monthly maintenance dosing (after Q2W induction) offers a distinct adherence advantage.
FDA-Approved Indications
- ● moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable
Why Ebglyss Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Dupixent (dupilumab) required as step therapy before IL-13–specific agent
- 2. EASI score, IGA, or BSA not documented at baseline (moderate-to-severe criteria)
- 3. Topical corticosteroid and calcineurin inhibitor trials not documented
- 4. Age criterion not documented (≥12 years required)
- 5. Concurrent systemic immunosuppressant use not addressed
- 6. Injection site training and patient enrollment not completed
What to Include in a Ebglyss Letter of Medical Necessity
Document atopic dermatitis diagnosis with baseline severity scores (EASI ≥16 for moderate, IGA ≥3, BSA ≥10%), prior topical therapy failures (topical corticosteroids and at least one topical calcineurin inhibitor or PDE4 inhibitor, with documented inadequate response or intolerance), prior biologic therapy history if step therapy applies (most plans require dupilumab trial — document dose, duration, and reason for transition), patient age ≥12 years, and absence of active infections or live vaccinations.
Key clinical evidence to cite:
- ✓ ADvocate 1 and ADvocate 2 Phase 3 trials — IGA 0/1 at Week 16: 38-41% vs 12-13% placebo; EASI-75: 58-63% vs 16-18%
- ✓ ADhere Phase 3 (with concomitant TCS) — IGA 0/1 at Week 16: 41.2% vs 22.1% placebo + TCS
- ✓ Selective IL-13 blockade — does not block IL-4 pathway (vs dupilumab's dual IL-4/IL-13 blockade)
- ✓ Monthly maintenance dosing after 16-week Q2W induction — adherence advantage
Relevant guidelines:
- 📖 AAD Atopic Dermatitis Guidelines (2023 update)
- 📖 EADV Atopic Dermatitis Guidelines
- 📖 JTF Atopic Dermatitis Practice Parameter
Ebglyss Prior Authorization Criteria
Standard criteria across major US payers for Ebglyss. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Dupixent (dupilumab) required as step therapy before IL-13–specific agent
- → Topical corticosteroid and calcineurin inhibitor trials not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ebglyss
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ebglyss Prior Authorization FAQ
Why was my Ebglyss prior authorization denied?
The most common denial reasons for Ebglyss are: Dupixent (dupilumab) required as step therapy before IL-13–specific agent; EASI score, IGA, or BSA not documented at baseline (moderate-to-severe criteria); Topical corticosteroid and calcineurin inhibitor trials not documented; Age criterion not documented (≥12 years required); Concurrent systemic immunosuppressant use not addressed; Injection site training and patient enrollment not completed.
What should a Ebglyss Letter of Medical Necessity include?
Document atopic dermatitis diagnosis with baseline severity scores (EASI ≥16 for moderate, IGA ≥3, BSA ≥10%), prior topical therapy failures (topical corticosteroids and at least one topical calcineurin inhibitor or PDE4 inhibitor, with documented inadequate response or intolerance), prior biologic therapy history if step therapy applies (most plans require dupilumab trial — document dose, duration, and reason for transition), patient age ≥12 years, and absence of active infections or live vaccinations.
Which payers cover Ebglyss?
Ebglyss is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.